TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38444429
Drug: CD19-CAR-DNT cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CAR-DNT cells (RJMty19) at dose level 4 (DL4)
Study: 38444519
Drug: Once-daily prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily prolonged-release tacrolimus (Envarsus) for 4 weeks
Study: 38444861
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell (DC) vaccination combined with carboplatin/paclitaxel chemotherapy
Study: 38444861
Drug: Carboplatin/paclitaxel chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/paclitaxel chemotherapy
Study: 38445317
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 8 mg (Group 2)
Study: 38445382
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) 24 International Units prior to each session of psychotherapy
Study: 38445541
Drug: Mitiperstat 5
Normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiperstat 5 mg once daily
Study: 38445651
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg low-dose melatonin administered 3 hours before the measured DLMO (measured DLMO group, n = 20)
Study: 38445651
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg low-dose melatonin administered 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20)
Study: 38445950
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care strategy of guideline-directed medical therapy up-titration
Study: 38445964
Drug: Once-weekly dordaviprone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dordaviprone
Study: 38445964
Drug: Twice-weekly dordaviprone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly dordaviprone
Study: 38446309
Drug: 90-g transplant
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-g transplant administered once to the colon (LI)
Study: 38446309
Drug: 90-g transplant
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-g transplant administered once to the duodenum (SI)
Study: 38446309
Drug: 90-g transplant
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-g transplant administered twice to the distal duodenum (repeated SI)
Study: 38446336
Drug: ICS-containing treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS-containing treatments
Study: 38446336
Drug: Non-ICS containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ICS containing treatments
Study: 38446341
Drug: Cenobamate (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (mean dose 262.5 mg/day)
Study: 38446388
Drug: HEC122505 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC122505 single ascending dose (5, 20, 50, 100, 200, 300, or 400 mg)
Study: 38446388
Drug: HEC122505 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC122505 multiple ascending dose (20, 50, or 100 mg once daily)
Study: 38446388
Drug: HEC122505 food
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC122505 food effect (100 mg single dose after a high-fat, high-calorie meal)
Study: 38446482
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (coronary angiography and revascularization if feasible, n=84)
Study: 38446482
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (medical treatment with coronary angiography only if recurrent ischemia, n=83)
Study: 38446675
Drug: Chemotherapy (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine and cisplatin or carboplatin)
Study: 38446860
Drug: In Vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Vivo treatment
Study: 38447095
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg oral nicotine pouches (ONP) for 8 weeks
Study: 38447095
Drug: Assessment-only control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment-only control (CC)
Study: 38447497
Drug: Aquatic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic Therapy (AT)
Study: 38447497
Drug: Land-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-Based Therapy (LBT)
Study: 38448064
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment with telemonitoring, home visits by a CPAP technician or nurse at CPAP initiation, followed up for 6 months.
Study: 38448965
Drug: Corneal crosslinking
Normalized name: hyaluronic acid, crosslinked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal crosslinking (CXL) treatment before transplantation, with possible repeat if insufficient reduction of corneal neovascularization is observed.
Study: 38448965
Drug: Corneal crosslinking
Normalized name: hyaluronic acid, crosslinked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal crosslinking (CXL) treatment with additional fine needle diathermy on the day of transplantation.
Study: 38449377
Drug: Pembrolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle plus SBRT delivered in 1-5 fractions starting on C1D15-28.
Study: 38449377
Drug: SBRT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT in addition to current therapy for patients who have started an immune checkpoint inhibitor within 60 days.
Study: 38449767
Drug: Blood levels
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood levels of prescribed drugs
Study: 38449916
Drug: Anti-PD-1 monoclonal
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monoclonal antibody infusions
Study: 38449910
Drug: Adaptations to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptations to the intervention (e.g., drop-in, open group format)
Study: 38450236
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day elemental Zn
Study: 38450236
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day elemental Zn
Study: 38450375
Drug: LDE-paclitaxel (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE-paclitaxel (IV infusion, paclitaxel dose: 175 mg/m2)
Study: 38450513
Drug: Mitapivat therapy
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitapivat therapy
Study: 38450551
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg tablet orally 3 hours before surgery
Study: 38450551
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 3 hours before surgery
Study: 38451273
Drug: Tiragolumab 600
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab 600 mg plus Atezolizumab 1200 mg intravenous every 3 weeks
Study: 38451491
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) to a dose of 50 Gy in 5 fractions every other day.
Study: 38451509
Drug: Water-free cyclosporine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-free cyclosporine ophthalmic solution, 0.1% (1 eye drop in each eye twice daily)
Study: 38451509
Drug: Vehicle (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (1 eye drop in each eye twice daily)
Study: 38451509
Drug: Water-free cyclosporine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-free cyclosporine ophthalmic solution, 0.1%
Study: 38451604
Drug: Lacosamide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (initial dose 50 mg orally twice a day, increasing to a maximum of 400 mg/day for 7 days)
Study: 38451604
Drug: Lacosamide +
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide + Opioid therapy
Study: 38452035
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg orally twice daily
Study: 38452059
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg daily with Sildenafil 100 mg daily
Study: 38452197
Drug: Fitusiran prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran prophylaxis (once-monthly 80 mg for 7 months)
Study: 38452283
Drug: β3-AR agonist
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β3-AR agonist mirabegron (300 mg/day) for 6 months
Study: 38452779
Drug: Tafenoquine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 300 mg (single dose)
Study: 38452779
Drug: 7-day primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day primaquine 0.5 mg/kg per day
Study: 38452779
Drug: Weekly primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly primaquine 0.75 mg/kg for 8 weeks
Study: 38452788
Drug: ASTX727 (cedazuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 (cedazuridine 100 mg and decitabine 35 mg) plus venetoclax 400 mg
Study: 38453435
Drug: VS-505 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-505 2.25 g/day
Study: 38453435
Drug: VS-505 1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-505 1.50 g/day
Study: 38453435
Drug: VS-505 4.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-505 4.50 g/day
Study: 38453435
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate 4.80 g/day
Study: 38453781
Drug: TOP2A+ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP2A+ group received FEC100 for 3 cycles followed by 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75 mg/m2).
Study: 38453781
Drug: TOP2A- group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP2A- group received the same chemotherapy regimen as TOP2A+ group.
Study: 38453781
Drug: TOP2A+ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP2A+ group received the same chemotherapy regimen as TOP2A- group.
Study: 38455033
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control arm receiving treatment information by mobile phone in addition to standard care.
Study: 38455366
Drug: Hemay022 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay022 at doses of 50-600 mg QD and 300 mg BID
Study: 38455850
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg tablets, three times per day (total dose of 1500 mg/day) for eight weeks
Study: 38455935
Drug: Biological, genetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological, genetic and microbiological analyses
Study: 38456042
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment linkage strategies
Study: 38456291
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (2 × 12 mg)
Study: 38456660
Drug: Navitoclax (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (250 mg daily days 1 to 28) and Trametinib (2 mg daily days 1 to 14)
Study: 38456703
Drug: Triple-dose CoronaVac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose CoronaVac
Study: 38456874
Drug: Discharge GDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge GDMT prescription after CABG surgery
Study: 38456874
Drug: Discharge GDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge GDMT prescription
Study: 38457177
Drug: Folic acid-fortified
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid-fortified iodized salt (300 µg/d of folic acid)
Study: 38457361
Drug: ML-ratio (monocytes-to-lymphocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-ratio (monocytes-to-lymphocytes ratio) (tenth decile > 2.02)
Study: 38458016
Drug: Biofeedback intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback intervention consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback for six weeks.
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group A (PIK3CA alterations)
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group B (cell cycle pathway alterations)
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group C (no druggable genetic alterations)
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group A
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group B
Study: 38458039
Drug: Durvalumab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (immune checkpoint inhibitor) in Group C
Study: 38458208
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus dexamethasone
Study: 38458208
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus dexamethasone
Study: 38458208
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus ibuprofen plus dexamethasone
Study: 38458408
Drug: Double etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double etonogestrel implant (136 mg)
Study: 38458408
Drug: Single etonogestrel
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single etonogestrel implant (68 mg)
Study: 38458577
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g cooked iron-fortified lentils (IFLs)
Study: 38458577
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g cooked noniron-fortified lentils (NIFLs)
Study: 38458635
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (nCRT) combined with PD-1 inhibitor toripalimab
Study: 38458788
Drug: KOOS Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOOS Activities of daily living score
Study: 38458796
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive medicines (AHT)
Study: 38458816
Drug: PRaG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor, GM-CSF)
Study: 38458816
Drug: PRaG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor)
Study: 38459072
Drug: S. sonnei
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB)
Study: 38459338
Drug: INS018_055 (small-molecule
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS018_055 (small-molecule TNIK inhibitor)
Study: 38459584
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy and imaging including both CT and MRI
Study: 38459869
Drug: Tegoprazan (TPZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (TPZ), amoxicillin, clarithromycin, and bismuth (300 mg twice daily)
Study: 38459869
Drug: Tegoprazan (TPZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (TPZ), amoxicillin, and clarithromycin (without bismuth)
Study: 38460082
Drug: Ensitrelvir 375
Normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir 375 mg single dose
Study: 38460092
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone treatment (GAHT) in transgender women (TW) after sex hormone inhibition and estradiol treatment.
Study: 38460092
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone treatment (GAHT) in transgender men (TM) after estrogen suppression and testosterone treatment.
Study: 38460525
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine (NVX-CoV2373 + NVX-CoV2540)
Study: 38460525
Drug: Prototype vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype vaccine (NVX-CoV2373)
Study: 38460974
Drug: Mechanical insufflation-exsufflation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical insufflation-exsufflation (MI-E) delivered by an experienced physiotherapist, with four cycles at a range of prescriptions.
Study: 38461094
Drug: 150-mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg daily aspirin
Study: 38461275
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Suicide Prevention (CTSP) + Services as Usual (SAU) (N=150)
Study: 38461313
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml natural aronia juice (verum, V) twice daily
Study: 38461731
Drug: Domperidone add-on
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone add-on 10-mg three times daily for 16 weeks
Study: 38461731
Drug: No add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: No add-on treatment (control)
Study: 38461843
Drug: Aflibercept 8
Normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 8 mg every 12 weeks (8q12)
Study: 38461843
Drug: Aflibercept 8
Normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 8 mg every 16 weeks (8q16)
Study: 38461843
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 8 weeks (2q8)
Study: 38461841
Drug: Aflibercept 8
Normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 8 mg every 12 weeks (8q12) vs 2q8
Study: 38461841
Drug: Aflibercept 8
Normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 8 mg every 16 weeks (8q16) vs 2q8
Study: 38462673
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampicin daily (flat dose)
Study: 38462751
Drug: Short regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short regimen containing high-dose moxifloxacin and clofazimine
Study: 38462760
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as prevention (TasP)
Study: 38462764
Drug: Eltrombopag, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag, daily fixed-dose for 6 months
Study: 38463163
Drug: Mixed RV1-RV5
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed RV1-RV5 vaccine schedules
Study: 38463541
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) + External Beam Radiation Therapy (EBRT, median dose: 50 Gy)
Study: 38509495
Drug: Therapeutic plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Study: 38465515
Drug: Apraglutide 5
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apraglutide 5 mg administered subcutaneously
Study: 38466266
Drug: Monthly intervention
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intervention (9 monthly video lessons and 1 week of self-monitoring per month)
Study: 38466266
Drug: Control intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control intervention (monthly online newsletters)
Study: 38466274
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (n=1541)
Study: 38466274
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n=1459)
Study: 38466972
Drug: Oral CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CBD therapy (2.5 mg per kg per day for 16 days)
Study: 38467003
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D supplementation (1000 mg of calcium carbonate with 400 IU of vitamin D)
Study: 38467131
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy (400 mg oral once daily after a 5-week ramp-up)
Study: 38467383
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (n=19)
Study: 38467383
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=23)